A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent must be obtained
Age \> 18 years
Histologically confirmed diagnosis of carcinoma of the prostate
Current (or previous) objective evidence of metastatic disease to the bone
Currently receiving 1st line hormonal therapy with LHRH agonists or other hormonal treatments
ECOG performance status of 0, 1, or 2
You may not be if
Patients with abnormal renal function as evidenced by either a serum creatinine determination 1.5 x or greater above the upper limit of normal or by a calculated creatinine clearance of 60 ml/minute or less
Liver function tests \>2.5 ULN, serum creatinine \>1.5 ULN.
Patients with another nonmalignant disease which would confound the evaluation of primary endpoints or prevent the patient complying with the protocol.
Known hypersensitivity to zoledronic acid or other bisphosphonates
Subjects who, in the opinion of the investigator, are unlikely to cooperate fully during the study
Clareo Health | A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
